Celldex Therapeutics, Inc. is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.

View all →   RSSRecent Releases
Dec 5, 2016 Theresa LaVallee, Ph.D., Joins Celldex Therapeutics' Senior Management Team
Dec 5, 2016 Celldex Presents Data on CDX-1140, a Novel CD40 Agonist Antibody for Hematologic and Solid Malignancies, at the American Society of Hematology (ASH) Annual Meeting
More →Upcoming Events
Details on upcoming events are not yet available.
Featured Financial Reports
Filing Date Title Type Size
Nov 7, 2016 Form 10-Q View HTML View PDF 350.7 KB Add to Briefcase
Feb 25, 2016 Form 10-K/A View HTML View PDF 1.1 MB Add to Briefcase
Add to Briefcase = add file to Briefcase